Sanofi SA (SAN) - Total Liabilities
Based on the latest financial reports, Sanofi SA (SAN) has total liabilities worth €55.10 Billion EUR as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sanofi SA - Total Liabilities Trend (1999–2025)
This chart illustrates how Sanofi SA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sanofi SA Competitors by Total Liabilities
The table below lists competitors of Sanofi SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Canadian Natural Resources Ltd
NYSE:CNQ
|
USA | $47.43 Billion |
|
Western Digital Corporation
NASDAQ:WDC
|
USA | $8.27 Billion |
|
Blackstone Group Inc
NYSE:BX
|
USA | $25.83 Billion |
|
Prosus N.V.
AS:PRX
|
Netherlands | €24.17 Billion |
|
Northrop Grumman Corporation
NYSE:NOC
|
USA | $34.70 Billion |
|
MediaTek Inc
TW:2454
|
Taiwan | NT$334.59 Billion |
|
China Yangtze Power Co Ltd
SHG:600900
|
China | CN¥335.78 Billion |
|
Bank of Montreal
NYSE:BMO
|
USA | $1.39 Trillion |
Liability Composition Analysis (1999–2025)
This chart breaks down Sanofi SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.27 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.77 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sanofi SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sanofi SA (1999–2025)
The table below shows the annual total liabilities of Sanofi SA from 1999 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €55.10 Billion | +0.28% |
| 2024-12-31 | €54.94 Billion | +5.43% |
| 2023-12-31 | €52.11 Billion | +1.05% |
| 2022-12-31 | €51.57 Billion | +0.70% |
| 2021-12-31 | €51.21 Billion | +0.10% |
| 2020-12-31 | €51.16 Billion | -4.60% |
| 2019-12-31 | €53.63 Billion | +2.40% |
| 2018-12-31 | €52.37 Billion | +25.98% |
| 2017-12-31 | €41.57 Billion | -11.45% |
| 2016-12-31 | €46.95 Billion | +6.43% |
| 2015-12-31 | €44.11 Billion | +7.26% |
| 2014-12-31 | €41.12 Billion | +5.39% |
| 2013-12-31 | €39.02 Billion | -9.13% |
| 2012-12-31 | €42.94 Billion | -3.05% |
| 2011-12-31 | €44.30 Billion | +38.53% |
| 2010-12-31 | €31.98 Billion | +1.18% |
| 2009-12-31 | €31.60 Billion | +17.41% |
| 2008-12-31 | €26.92 Billion | +10.84% |
| 2007-12-31 | €24.28 Billion | -14.65% |
| 2006-12-31 | €28.45 Billion | -29.97% |
| 2005-12-31 | €40.63 Billion | -7.42% |
| 2004-12-31 | €43.88 Billion | +1190.09% |
| 2003-12-31 | €3.40 Billion | -0.24% |
| 2002-12-31 | €3.41 Billion | -18.39% |
| 2001-12-31 | €4.18 Billion | +18.93% |
| 2000-12-31 | €3.51 Billion | +9.34% |
| 1999-12-31 | €3.21 Billion | -- |
About Sanofi SA
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting aga… Read more